检索结果-南通市图书馆

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

驱动应变桥传感器的信号调理IC

电子产品世界 2004年第7A期11卷 53-55页

作者： mark a.parsons Maxim公司

应变片传感器具有可靠、可重复和精确的特点,广泛用于制造、过程控制和科研领域.应变片传感器把应变转换为压力传感器、重量测量、力和转矩测量及材料分析所用的电信号.应变片只不过是一个电阻器,其值随粘贴材料的应变而变化.

关键词：应变片传感器驱动应变桥信号调理 MAX1452

12．世界冰川数据中心2020年未来发展宣言书

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

图书情报工作动态 2009年第2期 13-15页

作者： mark a.parsons 鲁超（编译）尚玮娇（编译）全国冰雪数据中心／世界冰川数据中心项目经理不详

我从三个相关的观点角度写这篇宣言书。首先，我以世界冰川数据中心的长期经理人的身份来写。从1957年开始作为保存国际地球物理文件和照片的图书馆，数据中心已经成为国家存储遥感和其他数字资源的大型数据中心。但我们仍然保持了文档... 详细信息

我从三个相关的观点角度写这篇宣言书。首先，我以世界冰川数据中心的长期经理人的身份来写。从1957年开始作为保存国际地球物理文件和照片的图书馆，数据中心已经成为国家存储遥感和其他数字资源的大型数据中心。但我们仍然保持了文档和照片的积极增长。第二，我是从当前的国际极地年（2007—2009年）的角度来写的。极地年是一个大型的国际化的和跨学科的科学项目，已经运行了两年，

关键词：数据中心宣言书冰川世界国际化地球物理数字资源科学项目

Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open- label, controlled trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Stroke & Vascular Neurology 2024年第1期9卷 82-89页

作者： Yunyun Xiong Bruce C V Campbell Marc Fisher Lee H Schwamm mark parsons Hao Li Yuesong Pan Xia Meng Xingquan Zhao Yongjun Wang Neurology Beijing Tiantan HospitalBeijingChina China National Clinical Research Center for Neurological Diseases BeijingChina Department of Medicine and Neurology The University of MelbourneMelbourneVictoriaAustralia Neurology Beth Israel Deaconess Medical CenterBostonMassachusettsUSA Department of Neurology and Comprehensive Stroke Center Massachusetts General HospitalBostonMassachusettsUSA Department of Neurology University of New South Wales South Western Sydney Clinical SchoolLiverpoolNew South WalesAustralia

Background and purpose Recombinant human TNK tissue-type plasminogen activator(rhTNK-tPA)was not inferior to alteplase for ischaemic stroke within *** study aimed to investigate the efficacy and safety of rhTNK-tPA in patients who had an ischaemic stroke due to large vessel occlusion(LVO)of anterior circulation beyond *** and design Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-III(TRACE III)is a multicentre,prospective,randomised,open-label,blind endpoint,controlled clinical *** who had an ischaemic stroke due to anterior circulation LVO(internal carotid artery,middle cerebral artery M1 and M2 segments)within 4.5–24hours from last known well(including wake-up stroke and no witness stroke)and with salvageable tissue(ischaemic core volume6s at 24 hours and NIHSS score change from baseline at *** outcomes are symptomatic intracerebral haemorrhage within 36 hours and mortality at 90 *** TRACE III will provide evidence for the efficacy and safety of rhTNK-tPA in patients who had an ischaemic strokes due to anterior circulation LVO beyond *** registration number NCT05141305.

关键词： Therapy random Rational

Early anticoagulation in patients with stroke and atrial fibrillation is associated with fewer ischaemic lesions at 1 month: the ATTUNE study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Stroke & Vascular Neurology 2024年第1期9卷 30-37,I0034页

作者： Angelos Sharobeam Longting Lin Christina Lam Carlos Garcia-Esperon Yash Gawarikar Ronak Patel Matthew Lee-Archer Andrew Wong Michael Roizman Amanda Gilligan Andrew Lee Kee Meng Tan Susan Day Christopher Levi Stephen M Davis mark parsons Bernard Yan Melbourne Brain Centre at Royal Melbourne Hospital ParkvilleVictoriaAustralia University of New South Wales South Western Sydney Clinical School LiverpoolNew South WalesAustralia Department of Neurology John Hunter HospitalNewcastleNew South WalesAustralia Department of Neurology Calvary Public HospitalCanberraAustralian Capital TerritoryAustralia Department of Neurology Northern Hospital EppingEppingVictoriaAustralia Department of Neurology Royal Brisbane and Women's HospitalHerstonQueenslandAustralia The University of Queensland School of Medicine HerstonQueenslandAustralia Neurosciences Clinical Institute Epworth HealthcareRichmondVirginiaAustralia Department of Neurology Austin HealthUniversity of MelbourneHeidelbergVictoriaAustralia Flinders University College of Medicine and Public Health AdelaideSouth AustraliaAustralia Department of Neurology Gold Coast University HospitalSouthportQueenslandAustralia The University of Sydney Northern Clinical School St LeonardsNew South WalesAustralia Department of Neurology and Neurophysiology Liverpool HospitalLiverpoolNew South WalesAustralia

Background The optimal time to commence anticoagulation in patients with atrial fibrillation(AF)after ischaemic stroke or transient ischaemic attack(TIA)is unclear,with guidelines differing in recommendations.A limitation of previous studies is the focus on clinically overt stroke,rather than radiologically obvious diffusion-weighted imaging ischaemic *** aimed to quantify silent ischaemic lesions and haemorrhages on MRI at 1month in patients commenced on early(5mL,regardless of anticoagulation *** Commencing anticoagulation<4days after stroke or TIA is associated with fewer ischaemic lesions at 1month in AF *** is no increased rate of haemorrhage with early *** results suggest that early anticoagulation after mild-to-moderate acute ischaemic stroke associated w

关键词： patients lesions ischaemic

Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-Ⅱ (TRACE Ⅱ): rationale and design

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Stroke & Vascular Neurology 2022年第1期7卷 71-76页

作者： Shuya Li Bruce C V Campbell Lee H Schwamm Marc Fisher mark parsons Hao Li Yuesong Pan Yongjun Wang China National Clinical Research Center for Neurological Diseases Beijing Tiantan HospitalCapital Medical UniversityBeijingChina Department of Neurology Beijing Tiantan HospitalCapital Medical UniversityBeijingChina Department of Medicine and Neurology University of MelbourneMelbourneVictoriaAustralia Department of Neurology and Comprehensive Stroke Center Massachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA Neurology Beth Israel Deaconess Medical CenterBostonMassachusettsUSA Department of Neurology Liverpool HospitalSouth Western Sydney Clinical SchoolSydneyNew South WalesAustralia

Background and purpose Tenecteplase(TNK)is a promising agent for treatment of acute ischaemic stroke(AIS).We hypothesised that recombinant human TNK tissue-type plasminogen activator(rhTNK-tPA)is non-inferior to rt-PA in achieving excellent functional outcome at 90 days,when administered within 4.5 hours of ischaemic stroke *** and design Tenecteplase Reperfusion therapy in Acute ischemic Cerebrovascular Events(TRACE)is a phase Ⅲ,multicentre,prospective,randomised,open-label,blinded-end point non-inferiority *** eligible for intravenous thrombolysis therapy are randomised to rhTNK-tPA 0.25 mg/kg(single bolus)to a maximum of 25 mg or rt-PA 0.9 mg/kg(10%bolus+90%infusion/1 hour)to a maximum of 90 *** considered necessary for the patient’s health may be given at the discretion of the investigator during 90-day *** outcomes The primary study outcome is excellent functional outcome defined as modified Rankin Scale(mRS)0–1 at 90 *** efficacy outcomes include favourable functional outcome defined as mRS≤2 at 90 days,ordinal distribution of mRS and major neurological improvement on the National Institutes of Health Stroke *** outcomes are symptomatic intracranial haemorrhage within 36 hours and death from any *** There is no completed registration study of TNK in AIS *** Ⅱ strives to provide evidence for a new drug application for rhTNK-tPA in AIS within 4.5 hours through a well-designed and rigorously executed randomised trial in China.

关键词： infusion acute rational

Implementation of regional Acute Stroke Care Map increases thrombolysis rates for acute ischaemic stroke in Chinese urban area in only 3 months

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Stroke & Vascular Neurology 2021年第1期6卷 87-94页

作者： Yi Sui Jianfeng Luo Chunyao Dong Liqiang Zheng Weijin Zhao Yao Zhang Ying Xian Huaguang Zheng Bernard Yan mark parsons Li Ren Ying Xiao Haoyue Zhu Lijie Ren Qi Fang Yi Yang Weidong Liu Bing Xu Department of Neurology Shenyang Brain HospitalShenyang Medical CollegeShenyangChina Department of Biostatistics Fudan University School of Public HealthShanghaiChina Department of Clinical Epidemiology Shengjing Hospital of China Medical UniversityShenyangChina Department of Neurology Duke Clinical Research InstituteDurhamNorth CarolinaUSA Department of Neurology Beijing Tiantan HospitalBeijingChina Department of Neurology at Melbourne Brain Center The University of Melbourne Medicine at Royal Melbourne HospitalParkvilleVictoriaAustralia Department of Neurology Shenzhen University 1st Affiliated HospitalShenzhen Second People’s HospitalShenzhenChina Department of Neurology The First Affiliated Hospital of Soochow UniversitySuzhouChina Department of Neurology The First Affiliated Hospital of Jilin UniversityChangchunChina Department of Neurosurgery Liaocheng People’s HospitalLiaochengChina

Background The rate of intravenous thrombolysis for acute ischaemic stroke remains low in *** investigated whether the implementation of a citywide Acute Stroke Care Map(ASCaM)is associated with an improvement of acute stroke care quality in a Chinese urban *** The ASCaM comprises 10 improvement strategies and has been implemented through a network consisting of 20 tertiary *** identified 7827 patients with ischaemic stroke admitted from April to October 2017,and 506 patients underwent thrombolysis were finally included for *** Compared with‘pre-ASCaM period’,we observed an increased rate of administration of tissue plasminogen activator within 4.5 hours(65.4% vs 54.5%;adjusted OR,1.724;95% CI 1.21 to 2.45;p=0.003)during‘ASCaM period’.In multivariate analysis models,‘ASCaM period’was associated with a significant reduction in onset-to door time(114.1±55.7 vs 135.7±58.4 min,p=0.0002)and onset-to needle time(ONT)(169.2±58.1 vs 195.6±59.3 min,p<0.0001).Yet no change was found in door-to needle *** outcomes such as symptomatic intracranial haemorrhage,favourable functional outcome(modified Rankin Scale≤2)and in-hospital mortality remained *** The implementation of ASCaM was significantly associated with increased rates of intravenous thrombolysis and shorter *** ASCaM may,in proof-of principle,serve as a model to reduce treatment delay and increase thrombolysis rates in Chinese urban areas and possibly other highly populated Asian regions.

关键词： thrombolysis needle admitted

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

如何用硅振荡器替代晶体和陶瓷谐振器

今日电子 2006年第4期 44-45页

作者： mark parsons Tony Allen Maxim公司

对于绝大多数微控制器时钟电路而言,硅振荡器是一种简单且有效的解决方案.与晶体和陶瓷谐振器不同,基于硅材料的定时器具有抗振动、抗撞击和抗电磁干扰的优点.同时,硅振荡器不需要严格匹配的定时元件和线路板走线.

关键词：陶瓷谐振器硅材料振荡器晶体抗电磁干扰时钟电路微控制器抗振动线路板定时

多模灌注影像评估基线皮质脊髓束损伤程度可预测轻型卒中静脉溶栓治疗的获益

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

多模灌注影像评估基线皮质脊髓束损伤程度可预测轻型卒中静脉溶栓...

Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial

2018年浙江省神经病学学术年会

作者：周颖张睿婷严慎强张美霞 mark W.parsons 楼敏浙江大学第二附属医院神经内科

目的 :轻型缺血性卒中(AIS)患者能否从静脉溶栓治疗中获益尚不明确。本研究旨在分析基线低灌体积<15 mL的AIS患者基线低灌和梗死累及皮质脊髓束(CST)的情况与溶栓治疗获益的关系。方法 :回顾国际多中心AIS数据库INSPIRE(在澳大利亚、中...

目的 :轻型缺血性卒中(AIS)患者能否从静脉溶栓治疗中获益尚不明确。本研究旨在分析基线低灌体积<15 mL的AIS患者基线低灌和梗死累及皮质脊髓束(CST)的情况与溶栓治疗获益的关系。方法 :回顾国际多中心AIS数据库INSPIRE(在澳大利亚、中国和加拿大的7个中心前瞻性收集基线行多模CT灌注的AIS患者数据),以及我中心前瞻性收集的基线行多模MR灌注的AIS换患者数据。纳入起病4.5小时内行多模CT灌注或MR灌注,且基线低灌体积<15 mL的AIS患者。由3名神经影像学专家判断基线低灌和梗死累及CST的情况,分成基线梗死累及CST、基线低灌累及CST但梗死未累及CST、基线低灌和梗死均未累及CST三个亚组。定义三月改良Rankin评分0-1为预后良好,比较总体和三个亚组接收静脉溶栓治疗与未接受溶栓治疗的患者的三月预后。结果 :回顾2011年至2017年共2654例AIS数据,最终412例纳入分析。其中,248例(60.2%)接受静脉溶栓治疗,164例(39.8%)未接受溶栓治疗。基线美国国立卫生研究院卒中量表(NIHSS)中位数5.0,316例(76.7%)三月预后良好。总体上,接受静脉溶栓组较未接受溶栓组,三月预后良好比例较低(溶栓72.2%vs不溶83.5%,OR=0.557,p=0.031)。亚组分析发现,基线低灌累及CST但梗死未累及CST组,接受静脉溶栓组较未接受溶栓组,三月预后良好比例较高(溶栓76.7%vs不溶47.1%,OR=3.914,p=0.049);基线梗死累及CST组,接受静脉溶栓组较未接受溶栓组,三月预后良好比例较低(溶栓32.4%vs不溶88.9%,OR=0.016,p=0.009);基线低灌和梗死均为累及CST组,接受静脉溶栓组与未接受溶栓组,三月预后良好比例无统计学差异(溶栓79.8%vs不溶87.7%,p=0.315)。结论 :基线低灌体积<15 mL的AIS患者,仅基线低灌累及CST且梗死未累及CST者可以从静脉溶栓治疗中获益,这可能为未来的溶栓决策提供信息。

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Stroke & Vascular Neurology 2022年第2期7卷 158-165页

作者： Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan mark W parsons Christopher Levi Geoffrey A Donnan Stephen M Davis Department of Medicine and Neurology Melbourne Brain Centre at The Royal Melbourne HospitalThe University of MelbourneParkvilleVictoriaAustralia Population Health and Immunity Division Walter and Eliza Hall Institute of Medical ResearchParkvilleVictoriaAustralia Ambulance Victoria MelbourneVictoriaAustralia Melbourne Medical School The University of MelbourneMelbourneVictoriaAustralia Stroke Division The Florey Institute of Neuroscience and Mental HealthParkvilleVictoriaAustralia Department of Neurology Christchurch HospitalChristchurchNew Zealand Department of Neurology Monash Medical CentreMonash UniversityClaytonVictoriaAustralia Department of Interventional Neuroradiology Liverpool HospitalLiverpoolNew South WalesAustralia Department of Neurology Royal Adelaide HospitalAdelaideSouth AustraliaAustralia Department of Neurology Princess Alexandra HospitalWoolloongabbaQueenslandAustralia Department of Neurology Box Hill HospitalEastern HealthBox HillVictoriaAustralia Stroke Centre and Department of Neurology National Taiwan University HospitalTaipeiTaiwan Department of Medicine Dunedin School of MedicineUniversity of OtagoWellingtonNew Zealand Department of Neurosurgery E-Da HospitalYanchaoKaohsiungTaiwan Department of Neurology Alfred HospitalMelbourneVictoriaAustralia Department of Clinical Neuroscience Monash University Central Clinical SchoolMelbourneVictoriaAustralia Department of Medicine Sunshine Coast University HospitalNambourQueenslandAustralia Department of Neurology Gold Coast University HospitalSouthportQueenslandAustralia Department of Neurology John Hunter HospitalThe University of NewcastleNewcastleNew South WalesAustralia Department of Neurosurgery China Medical University HospitalTaichungTaiwan Department of Internal Medicine Palmerston North HospitalPalmerston NorthNew Zealand Department of Neurology St Vincent's HospitalFitzroyVictoriaAustralia Department of Neurology Royal Prince Alfred HospitalCamperdownNew South WalesAustra

Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of *** acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma *** and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical *** In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with *** size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of *** adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 *** Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching *** efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT *** We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments.

关键词： placebo centre absolute